Differential activation of inflammatory pathways in A549 type II pneumocytes by <it>Streptococcus pneumoniae </it>strains with different adherence properties
Horvat Rebecca T, Reed Natalie A, Robson Rachel L
BMC Infectious Diseases · 2006
doi:10.1186/1471-2334-6-71 (opens in a new tab)
We email you when a new notice or a question about this paper appears.
Abstract
<p>Abstract</p> <p>Background</p> <p>Adherence of <it>Streptococcus pneumoniae </it>bacteria to lung cells is a first step in the progression from asymptomatic carriage to pneumonia. Adherence abilities vary widely among <it>S. pneumoniae </it>patient isolates. In this study, the binding properties of <it>S. pneumoniae </it>isolates and the effects of binding on activation of the Nuclear Factor-Kappa-B (NFκB) pathway and cytokine secretion by type II pneumocytes were measured.</p> <p>Methods</p> <p>Mechanisms of high- and low-binding <it>S. pneumoniae </it>adherence to A549 cells were investigated by blocking putative receptors on bacteria and host cells with antibody and by eluting choline-binding proteins off of bacterial surfaces. NFκB activation was measured by western blot and immunocytochemistry and cytokine secretion was detected by a protein array.</p> <p>Results</p> <p>This study shows that <it>S. pneumoniae </it>isolates from pneumonia patients (n = 298) can vary by as much as 1000-fold in their ability to bind to human lung epithelial cells. This difference resulted in differential activation of the NFκB pathway. High-, but not low-binding <it>S. pneumoniae </it>used Choline-binding protein A (CbpA) to bind to complement component C3 on epithelial cell surfaces. Interleukin-8 (IL-8) was the only cytokine secreted by cells treated with either low- or high-binding <it>S. pneumoniae</it>.</p> <p>Conclusion</p> <p>These results indicate that <it>S. pneumoniae </it>clinical isolates are not homogeneous in their interaction with host epithelial cells. The differential activation of host cells by high- and low-binding <it>S. pneumoniae </it>strains could have implications for the treatment of pneumococcal pneumonia and for vaccine development.</p>
Abstract licence: CC BY-NC-ND
Reads
Read by people on this page
None yet.
Checked or read by AI through naulon
None yet.
A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.
Are you an author?
Is this your paper?
Claim it to add your note and be paid when agents cite it. Free.